Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention

Fig. 3

DZNep treatment of transformed HBEC lines reprograms the transcriptome through chromatin remodeling affecting EZH2 and H3K27me3. Western blot showing the effect of treatment of HBEC2T and HBEC13T for 8 days with DMSO, UNC0642, EPZ6438, UNC0642 + EPZ6438, or DZNep on levels of G9a, EZH2, β-Actin, total histone H3, H3K27me3, and H3K9me2 (a). Densitometry quantitation of EZH2 (b) and (c) H3K27me3 levels in HBEC2T and HBEC13T cells treated with chromatin remodeling agents. Values are mean ± SEM (n = 2), *p < 0.05; **p < 0.01 compared to β-Actin or total histone H3. Ingenuity Pathway Analysis was used to identify pathways for differentially expressed genes following treatment of HBEC2T and HBEC13T with DZNep (d) or EPZ6438 + UNC0642 (e)

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us